Brown, Lisle/Cummings, Inc. Precigen, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Precigen, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 2,250 shares of PGEN stock, worth $2,160. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,250Holding current value
$2,160% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PGEN
# of Institutions
143Shares Held
144MCall Options Held
292KPut Options Held
53.8K-
Third Security, LLC83.5MShares$80.1 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD18.2MShares$17.4 Million1.57% of portfolio
-
Black Rock Inc. New York, NY10.2MShares$9.84 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.76MShares$6.49 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$2.97 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $200M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...